The clinical trial is investigating the use of allogenic Mesenchymal stromal cells in patients with a complication known as acute respiratory distress syndrome (ARDS) caused by coronavirus NEW DELHI : Researchers at Queen's University Belfast are leading a UK-wide clinical trial, offering an innovative cell therapy treatment for Covid-19 patients with acute respiratory failure.
This clinical trial — led by Professor Danny McAuley and Professor Cecilia O'Kane, both researchers from the Wellcome-Wolfson Institute for Experimental Medicine at Queen's — is investigating the use of allogenic Mesenchymal stromal cells (MSCs) in patients with a complication known as acute respiratory distress syndrome (ARDS) caused by coronavirus.